Bavarian Nordic

About Bavarian Nordic

Bavarian Nordic is a leading biotechnology company focused on the development and production of innovative vaccines for infectious diseases and cancer. Established in 1994, the company has made significant strides in the field of immunotherapy, particularly with its proprietary technology platform that enables the creation of live virus vaccines.

The company’s core activities revolve around the research, development, and commercialization of vaccines that address unmet medical needs. Bavarian Nordic’s flagship product, Imvamune®, is a non-replicating smallpox vaccine that has been approved for use in various countries and is stockpiled by governments worldwide as a preparedness measure against potential bioterrorism threats.

In addition to its work on smallpox, Bavarian Nordic is actively engaged in developing vaccines for other infectious diseases, including Ebola and COVID-19. The company collaborates with various governmental and non-governmental organizations to enhance global health security through its innovative vaccine solutions.

Bavarian Nordic is also pioneering efforts in cancer immunotherapy, with a focus on developing personalized cancer vaccines that harness the body’s immune system to target and destroy cancer cells. This approach represents a promising frontier in cancer treatment, aiming to improve patient outcomes and quality of life.

With a commitment to scientific excellence and innovation, Bavarian Nordic strives to be at the forefront of vaccine development. The company’s vision is to create a healthier future by providing effective and safe vaccines that protect against infectious diseases and cancer.

Headquartered in Denmark, Bavarian Nordic operates globally, with a strong presence in the UK and other key markets. The company is dedicated to fostering partnerships and collaborations that drive advancements in vaccine technology and public health initiatives.

Through its ongoing research and development efforts, Bavarian Nordic aims to expand its portfolio of vaccine candidates and contribute to the global fight against infectious diseases and cancer.